These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35894705)

  • 1. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
    Hoffman TW; Meek B; Rijkers GT; van Kessel DA
    Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial.
    Drenko P; Kacer M; Kielberger L; Vlas T; Topolcan O; Kucera R; Reischig T
    Transpl Infect Dis; 2023 Oct; 25(5):e14150. PubMed ID: 37724748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients.
    Hirama T; Akiba M; Shundo Y; Watanabe T; Watanabe Y; Oishi H; Niikawa H; Okada Y
    J Infect Chemother; 2022 Aug; 28(8):1153-1158. PubMed ID: 35599079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2022 Jun; 84(6):795-813. PubMed ID: 35405168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection.
    Goda Y; Nakajima D; Tanaka S; Yamada Y; Yutaka Y; Unagami K; Yoshikawa M; Egawa H; Date H
    Gen Thorac Cardiovasc Surg; 2023 Apr; 71(4):251-257. PubMed ID: 36289168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
    Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
    Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of mRNA Vaccine Immunogenicity in Solid Organ Transplant Recipients.
    Tsoutsoura P; Xagas E; Roussos S; Hatzakis A; Gourzi P; Boletis IN; Marinaki S
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374279
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
    Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.